Background: Previous studies investigated the associations of interleukin-10 (IL-10) polymorphisms with different types of cancer, indicating an influence on cancer risk. IL-10-3575T>A (rs1800890) has been studied concerning a potential implication in terms of some cancer site risks, but the results from single studies are contradictory. Methods: Eligible articles were identified by a search of the PubMed, Web of Science, and Chinese National Knowledge Infrastructure (CNKI) databases until November 30, 2014. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the cancer risk by cancer sites, ethnicity, and other study features. Results: We identified 15 published studies to research the link of the IL-10-3575T>A polymorphism with cancer risk. Our meta-analysis indicated that the IL-10-3575T>A polymorphism has a significant association with decreased melanoma risk in the heterozygote model (OR=0.67, 95% CI=0.49-0.92, p=0.02) and dominant model (OR=0.70, 95% CI=0.52-0.95, p=0.01), but increased diffuse large B-cell lymphoma (DLBCL) risk in all the different genetic models. Conclusion: Our analysis suggests that the IL-10-3575T>A mutation may associate with melanoma and DLBCL and exert a differential effect in different cancer sites. However, other factors may influence the association, and large-scale multicenter with adequate methodological quality studies are needed to confirm the impact on cancer susceptibility.
Get full access to this article
View all access options for this article.
References
1.
CaoHY, ZouP, ZhouH (2013) Genetic association of interleukin-10 promoter polymorphisms and susceptibility to diffuse large B-cell lymphoma: a meta-analysis. Gene, 519:288-294.
2.
CrivelloA, GiacaloneA, VaglicaM, et al. (2006) Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma. Ann N Y Acad Sci, 1089:98-103.
3.
de VisserKE, EichtenA, CoussensLM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer, 6:24-37.
4.
EggerM, DaveySG, SchneiderM, MinderC (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ, 315:629-634.
5.
EnnasMG, MoorePS, ZuccaM, et al. (2008) Interleukin-1B (IL1B) and interleukin-6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia. Hematol Oncol, 26:98-103.
6.
FerlayJ, SoerjomataramI, DikshitR, et al. (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 136:E359-E386.
7.
FernbergP, ChangET, DuvefeltK, et al. (2010) Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma. Cancer Causes Control, 21:759-769.
8.
GaliziaG, OrdituraM, RomanoC, et al. (2002) Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol, 102:169-178.
9.
GibsonAW, EdbergJC, WuJ, WestendorpRG, HuizingaTW, KimberlyRP (2001) Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol, 166:3915-3922.
10.
GuF, QureshiAA, NiuT, et al. (2008) Interleukin and interleukin receptor gene polymorphisms and susceptibility to melanoma. Melanoma Res, 18:330-335.
11.
HigginsJP, ThompsonSG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med, 21:1539-1558.
12.
HowellWM, TurnerSJ, BatemanAC, TheakerJM (2001) IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun, 2:25-31.
13.
HuangS, UllrichSE, Bar-EliM (1999) Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res, 19:697-703.
14.
KubeD, HuaTD, vonBF, et al. (2008) Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study. Clin Cancer Res, 14:3777-3784.
15.
LanQ, ZhengT, RothmanN, et al. (2006) Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood, 107:4101-4108.
16.
Lech-MarandaE, MlynarskiW, Grzybowska-IzydorczykO, et al. (2013) Polymorphisms of TNF and IL-10 genes and clinical outcome of patients with chronic lymphocytic leukemia. Genes Chromosomes Cancer, 52:287-296.
17.
LiangXS, CaporasoN, McMasterML, et al. (2009) Common genetic variants in candidate genes and risk of familial lymphoid malignancies. Br J Haematol, 146:418-423.
18.
MahajanR, El-OmarEM, LissowskaJ, et al. (2008) Genetic variants in T helper cell type 1, 2 and 3 pathways and gastric cancer risk in a Polish population. Jpn J Clin Oncol, 38:626-633.
19.
MocellinS, MarincolaF, RossiCR, NittiD, LiseM (2004) The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev, 15:61-76.
20.
MocellinS, PanelliMC, WangE, NagorsenD, MarincolaFM (2003) The dual role of IL-10. Trends Immunol, 24:36-43.
21.
MooreKW, de Waal MalefytR, CoffmanRL, O'GarraA (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol, 19:683-765.
22.
MortonLM, TurnerJJ, CerhanJR, et al. (2007) Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood, 110:695-708.
23.
MunafoMR, FlintJ (2004) Meta-analysis of genetic association studies. Trends Genet, 20:439-444.
24.
NietersA, BeckmannL, DeegE, BeckerN (2006) Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun, 7:615-624.
25.
PharoahPD, DunningAM, PonderBA, EastonDF (2004) Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer, 4:850-860.
26.
PurdueMP, LanQ, KrickerA, et al. (2007) Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis, 28:704-712.
27.
RothmanN, SkibolaCF, WangSS, et al. (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol, 7:27-38.
28.
SaraivaM, O'GarraA (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol, 10:170-181.
29.
SchoofN, vonBF, KonigIR, et al. (2009) Distal and proximal interleukin (IL)-10 promoter polymorphisms associated with risk of cutaneous melanoma development: a case-control study. Genes Immun, 10:586-590.
30.
SmythMJ, CretneyE, KershawMH, HayakawaY (2004) Cytokines in cancer immunity and immunotherapy. Immunol Rev, 202:275-293.
31.
SugimotoM, FurutaT, ShiraiN, et al. (2007) Effects of interleukin-10 gene polymorphism on the development of gastric cancer and peptic ulcer in Japanese subjects. J Gastroenterol Hepatol, 22:1443-1449.
32.
TsilidisKK, HelzlsouerKJ, SmithMW, et al. (2009). Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control, 20:1739-1751.
33.
TurnerDM, WilliamsDM, SankaranD, LazarusM, SinnottPJ, HutchinsonIV (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet, 24:1-8.
34.
WangSS, CerhanJR, HartgeP, et al. (2006) Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res, 66:9771-9780.
35.
YriOE, EkstromPO, HildenV, et al. (2012) Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma. Leuk Lymphoma, 53:1934-1944.
